Chinook Therapeutics slips on pausing patient dosing in kidney disorder drug trial

Chinook Therapeutics

11/04/2023 13:40

** Chinook Therapeutics Inc's  KDNY.O  shares fall 7.9% to
$19.90 premarket
    ** Company voluntarily paused dosing in experimental therapy
CHK-336's early-stage trial for hyperoxaluria treatment
    ** Dosing halt in healthy volunteers to allow thorough
investigation of serious adverse event (SAE) that occurred in a
single subject, company says 
    ** Hyperoxaluria, characterized by recurrent kidney and
bladder stones, is a rare genetic metabolic disorder resulting
from buildup of a substance called oxalate in the urinary
bladder
    ** Company says SAE had rapid onset and follow up of the
subject is ongoing; adds the event has been reported to U.S. FDA
    ** Underlying cause of the event is being investigated as a
potential extreme immune response to the study drug - Chinook
    ** As of last close, company's shares down 17.6% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))